Association between subjective well-being and prefrontal function during a cognitive task in schizophrenia: A multi-channel near-infrared spectroscopy study

Schizophrenia Research

Volumn 149, Issue 1-3, 2013, Pages 180-185

  Pu, Shenghong ^a   Nakagome, Kazuyuki ^b   Yamada, Takeshi ^a   Yokoyama, Katsutoshi ^a   Itakura, Megumi ^a   Satake, Takahiro ^a   Ishida, Hisahito ^a   Nagata, Izumi ^a   Kaneko, Koichi ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Near infrared spectroscopy (NIRS); Prefrontal function; Schizophrenia; Subjective Well being under Neuroleptic drug treatment Short form (SWNS); Verbal fluency task

Indexed keywords

ARIPIPRAZOLE; BLONANSERIN; CHLORPROMAZINE; HEMOGLOBIN; OLANZAPINE; PEROSPIRONE; RISPERIDONE;

52 CHANNEL NEAR INFRARED SPECTROSCOPY; ADULT; ARTICLE; BILATERAL DORSOLATERAL PREFRONTAL CORTEX; BRAIN FUNCTION; CLINICAL ARTICLE; COGNITION; DISEASE ASSOCIATION; FEMALE; FRONTOPOLAR PREFRONTAL CORTEX; FUNCTIONAL ASSESSMENT; HEMOGLOBIN DETERMINATION; HUMAN; LANGUAGE ABILITY; LEFT VENTROLATERAL PREFRONTAL CORTEX; MALE; MENTAL TASK; NEAR INFRARED SPECTROSCOPY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; SCHIZOPHRENIA; SCORING SYSTEM; SUBJECTIVE WELL BEING UNDER NEUROLEPTIC DRUG TREATMENT SHORT FORM;

NEAR-INFRARED SPECTROSCOPY (NIRS); PREFRONTAL FUNCTION; SCHIZOPHRENIA; SUBJECTIVE WELL-BEING UNDER NEUROLEPTIC DRUG TREATMENT SHORT FORM (SWNS); VERBAL FLUENCY TASK;

ADULT; BRAIN MAPPING; COGNITION DISORDERS; FEMALE; HEMOGLOBINS; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PREFRONTAL CORTEX; SCHIZOPHRENIA; SPECTROSCOPY, NEAR-INFRARED; STATISTICS AS TOPIC; VERBAL BEHAVIOR;

EID: 84881260849     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.06.036     Document Type: Article

References (48)

1. Abele A. Auswirkungen von Wohlbefinden oder: Kann gute Laune schaden?. Wohlbefinden. Theorie, Empirie, Diagnostik 1991, 297-325. Juventa, Weinhiem. A. Abele, P. Becker (Eds.).
2. Awad A.G., Voruganti L.N., Heslegrave R.J. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual. Life Res. 1997, 6(1):21-26.
3. Boas D.A., Dale A.M., Franceschini M.A. Diffuse optical imaging of brain activation: approaches to optimizing image sensitivity, resolution, and accuracy. NeuroImage 2004, 23:275-288.
4. Boyer L., Richieri R., Faget C., Padovani R., Vaillant F., Mundler O., Lançon C., Auquier P., Guedj E. Functional involvement of superior temporal sulcus in quality of life of patients with schizophrenia. Psychiatry Res. 2012, 202:155-160.
5. Brekke J.S., Levin S., Wolkon G.H., Sobel E., Slade E. Psychosocial functioning and subjective experience in schizophrenia. Schizophr. Bull. 1993, 19(3):599-608.
6. Burns T. Evolution of outcome measures in schizophrenia. Br. J. Psychiatry Suppl. 2007, 50:1-6.
7. Davidson R.J. Well-being and affective style: neural substrates and biobehavioural correlates. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2004, 359:1395-1411.
8. de Haan L., Lavalaye J., Linszen D., Dingemans P.M., Booij J. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am. J. Psychiatry 2000, 157:1019-1020.
9. de Haan L., Weisfelt M., Dingemans P.M., Linszen D.H., Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology (Berl) 2002, 162:24-28.
10. de Haan L., van Nimwegen L., van Amelsvoort T., Dingemans P., Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 2008, 41:1-4.
11. Diener E. Subjective well-being. Psychol. Bull. 1984, 95:542-575.
12. Durstewitz D., Seamans J.K. The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia. Biol. Psychiatry 2008, 64:739-749.
13. Hall H., Farde L., Halldin C., Hurd Y.L., Pauli S., Sedvall G. Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse 1996, 23:115-123.
14. Higuchi Y., Sumiyoshi T., Kawasaki Y., Matsui M., Arai H., Kurachi M. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300. Schizophr. Res. 2008, 101:320-330.
15. Hock C., Villringer K., Müller-Spahn F., Wenzel R., Heekeren H., Schuh-Hofer S., Hofmann M., Minoshima S., Schwaiger M., Dirnagl U., Villringer A. Decrease in parietal cerebral hemoglobin oxygenation during performance of a verbal fluency task in patients with Alzheimer's disease monitored by means of near-infrared spectroscopy (NIRS)-correlation with simultaneous rCBF-PET measurements. Brain Res. 1997, 755:293-303.
16. Hofer A., Kemmler G., Eder U., Edlinger M., Hummer M., Fleischhacker W.W. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 2004, 65:932-939.
17. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull. 1987, 13:261-276.
18. Kluge M., Wehmeier P.M., Dittmann R.W., Langer F., Czekalla J., Lehmann M., Kessler F.H., Beyenburg S., Naber D. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. Pharmacopsychiatry 2005, 38:6-12.
19. Kurtz M.M., Tolman A. Neurocognition, insight into illness and subjective quality-of-life in schizophrenia: what is their relationship?. Schizophr. Res. 2011, 127:157-162.
20. Kurtz M.M., Wexler B.E., Fujimoto M., Shagan D.S., Seltzer J.C. Symptoms versus neurocognition as predictors of change in life skills in schizophrenia after outpatient rehabilitation. Schizophr. Res. 2008, 102:303-311.
21. Lambert M., Schimmelmann B.G., Naber D., Schacht A., Karow A., Wagner T., Czekalla J. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J. Clin. Psychiatry 2006, 67:1690-1697.
22. Mizrahi R., Mamo D., Rusjan P., Graff A., Houle S., Kapur S. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int. J. Neuropsychopharmacol. 2009, 12(5):715-721.
23. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int. Clin. Psychopharmacol. 1995, 10(Suppl. 3):133-138.
24. Naber D., Moritz S., Lambert M., Pajonk F.G., Holzbach R., Mass R., Andresen B. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr. Res. 2001, 50:79-88.
25. Naber D., Riedel M., Klimke A., Vorbach E.U., Lambert M., Kühn K.U., Bender S., Bandelow B., Lemmer W., Moritz S., Dittmann R.W. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr. Scand. 2005, 111:106-115.
26. Nieoullon A., Coquerel A. Dopamine: a key regulator to adapt action, emotion, motivation and cognition. Curr. Opin. Neurol. 2003, 16(Suppl. 2):3-9.
27. Ohmae E., Ouchi Y., Oda M., Suzuki T., Nobesawa S., Kanno T., Yoshikawa E., Futatsubashi M., Ueda Y., Okada H., Yamashita Y. Cerebral hemodynamics evaluation by near-infrared time-resolved spectroscopy: correlation with simultaneous positron emission tomography measurements. NeuroImage 2006, 29:697-705.
28. Okada E., Delpy D.T. Near-infrared light propagation in an adult head model. II. Effect of superficial tissue thickness on the sensitivity of the near-infrared spectroscopy signal. Appl. Opt. 2003, 42:2915-2922.
29. Okamoto M., Dan I. Automated cortical projection of head-surface locations for transcranial functional brain mapping. NeuroImage 2005, 26:18-28.
30. Okamoto M., Dan H., Sakamoto K., Takeo K., Amita T., Oda I., Konishi I., Sakamoto K., Isobe S., Suzuki T., Kohyama K., Dan I. Three-dimensional probabilistic anatomical cranio-cerebral correlation via the international 10-20 system oriented for transcranial functional brain mapping. NeuroImage 2004, 21:99-111.
31. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971, 9:97-113.
32. Pu S., Matsumura H., Yamada T., Ikezawa S., Mitani H., Adachi A., Nakagome K. Reduced frontopolar activation during verbal fluency task associated with poor social functioning in late-onset major depression: a multi-channel near-infrared spectroscopy study. Psychiatry Clin. Neurosci. 2008, 62:728-737.
33. Pu S., Yamada T., Yokoyama K., Matsumura H., Mitani H., Adachi A., Kaneko K., Nakagome K. Reduced prefrontal cortex activation during the working memory task associated with poor social functioning in late-onset depression: multi-channel near-infrared spectroscopy study. Psychiatry Res. 2012, 203(2-3):222-228.
34. Singh A.K., Dan I. Exploring the false discovery rate in multichannel NIRS. NeuroImage 2006, 33:542-549.
35. Strangman G., Boas D.A., Sutton J.P. Non-invasive neuroimaging using near-infrared light. Biol. Psychiatry 2002, 52:679-693.
36. Strangman S., Culver J.P., Thompson J.H., Boas D.A. A quantitative comparison of simultaneous BOLD fMRI and NIRS recording during functional brain activation. NeuroImage 2002, 17:719-731.
37. Sumiyoshi T., Higuchi Y., Itoh T., Matsui M., Arai H., Suzuki M., Kurachi M., Sumiyoshi C., Kawasaki Y. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sLORETA. Psychiatry Res. 2009, 172:180-183.
38. Takizawa R., Kasai K., Kawakubo Y., Marumo K., Kawasaki S., Yamasue H., Fukuda M. Reduced frontopolar activation during verbal fluency task in schizophrenia: a multi-channel near-infrared spectroscopy study. Schizophr. Res. 2008, 99:250-262.
39. Tolman A.W., Kurtz M.M. Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr. Bull. 2012, 38:304-315.
40. Toronov V., Webb A., Choi J.H., Wolf M., Michalos A., Gratton E., Hueber D. Investigation of human brain hemodynamics by simultaneous near-infrared spectroscopy and functional magnetic resonance imaging. Med. Phys. 2001, 28:521-527.
41. Tsuzuki D., Jurcak V., Singh A.K., Okamoto M., Watanabe E., Dan I. Virtual spatial registration of stand-alone fNIRS data to MNI space. NeuroImage 2007, 34:1506-1518.
42. Urry H.L., Nitschke J.B., Dolski I., Jackson D.C., Dalton K.M., Mueller C.J., Rosenkranz M.A., Ryff C.D., Singer B.H., Davidson R.J. Making a life worth living: neural correlates of well-being. Psychol. Sci. 2004, 15:367-372.
43. Villringer K., Minoshima S., Hock C., Obrig H., Ziegler S., Dirnagl U., Schwaiger M., Villringer A. Assessment of local brain activation. A simultaneous PET and near-infrared spectroscopy study. Adv. Exp. Med. Biol. 1997, 413:149-153.
44. Voruganti L.N., Awad A.G. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia-findings from an in vivo SPECT study. Schizophr. Res. 2006, 88:179-186.
45. Watanabe M., Matsumura H. Reliability and validity of subjective well-being under neuroleptic drug treatment short form, Japanese version (SWNS-J). J. Clin. Psychopharmacol. 2003, 6:905-912. (in Japanese).
46. Winterer G., Weinberger D.R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 2004, 27:683-690.
47. Yamashita Y., Maki A., Ito Y., Watanabe E., Koizumi H. Noninvasive near-infrared topography of human brain activity using intensity modulation spectroscopy. Opt. Eng. 1996, 35:1046-1049.
48. Zhao H., Tanikawa Y., Gao F., Onodera Y., Sassaroli A., Tanaka K., Yamada Y. Maps of optical differential pathlength factor of human adult forehead, somatosensory motor and occipital regions at multi-wavelengths in NIR. Phys. Med. Biol. 2002, 47:2075-2093.